BIO vs ERNA · rev $2.58B vs P/E 0.0, rev $582.0K
BIO (BIO) versus Eterna Therapeutics Inc (ERNA) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Eterna Therapeutics Inc (ERNA) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported ERNA revenue for 2024-12-31 was $582.0K. Net income was -$44.5M. Revenue was up 755.9% from 2023-12-31 to 2024-12-31. ERNA currently screens at market cap $6.9M and trailing P/E 0.0.
BIO currently screens at market cap $0. ERNA currently screens at market cap $6.9M and trailing P/E 0.0.
Not investment advice. Open the BIO and ERNA stock pages for the full models.
Not investment advice.